Medicaid dominates coverage of Novo, Lilly weight-loss drugs

The data shows that state Medicaid programs are the largest source of coverage for weight-loss drugs, providing access to over 31 million people in the U.S.

Despite the growing popularity of weight-loss drugs, private health plans only cover about 13.7 million people, indicating a significant gap compared to government-funded health plans.

Kathy Hempstead highlighted the disparity between government and private health plans, noting that many employers are hesitant to add the cost of weight-loss treatment due to rising insurance premiums.

The introduction of Wegovy and Zepbound is changing obesity treatment, with unprecedented efficacy enabling significant weight loss for many patients.

Read at Fast Company